These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 28533357)

  • 21. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
    Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
    Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppressive role of BDNF in therapy-induced neuroendocrine prostate cancer.
    Liu YN; Chen WY; Liu MK; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Wang WH; Abou-Kheir W; Wen YC
    Mol Oncol; 2024 Jun; 18(6):1665-1686. PubMed ID: 38381121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.
    Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W
    Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
    Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
    Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer.
    Wen J; Huang G; Liu S; Wan J; Wang X; Zhu Y; Kaliney W; Zhang C; Cheng L; Wen X; Lu X
    J Pathol Clin Res; 2020 Jul; 6(3):171-177. PubMed ID: 32149481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
    Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
    Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially.
    Zhao W; Xu Y; Xu J; Wu D; Zhao B; Yin Z; Wang X
    Int Immunopharmacol; 2015 Jun; 26(2):314-21. PubMed ID: 25891236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
    Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
    Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.
    Wang Y; Schafer CC; Hough KP; Tousif S; Duncan SR; Kearney JF; Ponnazhagan S; Hsu HC; Deshane JS
    J Immunol; 2018 Jul; 201(1):278-295. PubMed ID: 29752311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and characterization of B220
    Zhang Z; Huang X; Wang E; Huang Y; Yang R
    Oncoimmunology; 2021 Apr; 10(1):1912472. PubMed ID: 33948392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
    Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
    Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The spleen contributes to the increase in PMN-MDSCs in orthotopic H22 hepatoma mice.
    Li BH; Jiang W; Zhang S; Huang N; Sun J; Yang J; Li ZF
    Mol Immunol; 2020 Sep; 125():95-103. PubMed ID: 32659598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
    Peek EM; Song W; Zhang H; Huang J; Chin AI
    Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.
    Zhang Y; Guoqiang L; Sun M; Lu X
    Cancer Biol Med; 2020 Feb; 17(1):32-43. PubMed ID: 32296575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.